Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  35,990 results for ""RITUXIMAB""

Your Filters

Publisher : wiley-blackwell
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Editorial & Opinion

Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab.

  • Authors : Gordilho JO; Department of Dermatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.; Miyamoto D

Subjects: Epidermolysis Bullosa* ; Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/diagnosis ; Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/Epidermolysis Bullosa Acquisita*/drug therapy

  • Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Jan; Vol. 38 (1), pp. e45-e47. Date of Electronic Publication: 2023 Aug Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.

  • Authors : Riise J; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Meyer S

Subjects: CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/immunology ; COVID-19*/COVID-19*/COVID-19*/prevention & control ; COVID-19 Vaccines*/COVID-19 Vaccines*/COVID-19 Vaccines*/immunology

  • Source: British journal of haematology [Br J Haematol] 2022 Jun; Vol. 197 (6), pp. 697-708. Date of Electronic Publication: 2022 Mar 21.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Report

Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.

  • Authors : Moore DC; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.; Soni AC

Subjects: Adenine/Adenine/Adenine/*analogs & derivatives ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Leg/Leg/Leg/*pathology

  • Source: British journal of haematology [Br J Haematol] 2022 Feb; Vol. 196 (4), pp. e30-e33. Date of Electronic Publication: 2021 Oct 12.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Report

Clinical outcome and B-cell kinetics in intercellular immunoglobulin A dermatosis treated with rituximab.

  • Authors : Lee SJ; Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.; Lee A

Subjects: B-Lymphocytes* ; Immunoglobulin A* ; Rituximab*/Rituximab*/Rituximab*/therapeutic use

  • Source: The Journal of dermatology [J Dermatol] 2022 Jan; Vol. 49 (1), pp. e22-e23. Date of Electronic Publication: 2021 Oct 21.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7600545 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.

  • Authors : Takezaki T; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Nakazaki K

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Bendamustine Hydrochloride/Bendamustine Hydrochloride/Bendamustine Hydrochloride/*therapeutic use ; Lymphoma, Follicular/Lymphoma, Follicular/Lymphoma, Follicular/*drug therapy

  • Source: Hematological oncology [Hematol Oncol] 2021 Oct; Vol. 39 (4), pp. 465-472. Date of Electronic Publication: 2021 May 02.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B-cell lymphoma in the rituximab era.

  • Authors : Guan Q; Departments of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China.; Hong Y

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*therapeutic use ; Lymphoma, Large B-Cell, Diffuse/Lymphoma, Large B-Cell, Diffuse/Lymphoma, Large B-Cell, Diffuse/*drug therapy ; Lymphoma, Large B-Cell, Diffuse/Lymphoma, Large B-Cell, Diffuse/Lymphoma, Large B-Cell, Diffuse/*radiotherapy

  • Source: Hematological oncology [Hematol Oncol] 2021 Oct; Vol. 39 (4), pp. 490-497. Date of Electronic Publication: 2021 Apr 27.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Report

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.

  • Authors : Morabito F; Biothecnology Research Unit, AO of Cosenza, Cosenza, Italy.; Hematology and Bone Marrow Transplant Unit, Hemato-Oncology Department, Augusta Victoria Hospital, East Jerusalem, Israel.

Subjects: Adenine/Adenine/Adenine/*analogs & derivatives ; Bendamustine Hydrochloride/Bendamustine Hydrochloride/Bendamustine Hydrochloride/*therapeutic use ; Leukemia, Lymphocytic, Chronic, B-Cell/Leukemia, Lymphocytic, Chronic, B-Cell/Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy

  • Source: American journal of hematology [Am J Hematol] 2021 Aug 01; Vol. 96 (8), pp. E269-E272. Date of Electronic Publication: 2021 May 03.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).

  • Authors : Boccomini C; SC Ematologia AOU Città della Salute e della Scienza di Torino, Torino, Italy.; Ladetto M

Subjects: Bendamustine Hydrochloride/Bendamustine Hydrochloride/Bendamustine Hydrochloride/*therapeutic use ; Lymphoma, Follicular/Lymphoma, Follicular/Lymphoma, Follicular/*drug therapy ; Mitoxantrone/Mitoxantrone/Mitoxantrone/*therapeutic use

  • Source: British journal of haematology [Br J Haematol] 2021 Apr; Vol. 193 (2), pp. 280-289. Date of Electronic Publication: 2021 Jan 21.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial.

  • Authors : Cheshmavar M; Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Subjects: Glatiramer Acetate/Glatiramer Acetate/Glatiramer Acetate/*therapeutic use ; Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*therapeutic use ; Multiple Sclerosis, Chronic Progressive/Multiple Sclerosis, Chronic Progressive/Multiple Sclerosis, Chronic Progressive/*drug therapy

  • Source: Acta neurologica Scandinavica [Acta Neurol Scand] 2021 Feb; Vol. 143 (2), pp. 178-187. Date of Electronic Publication: 2020 Oct 27.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 0370336 Publication Model: Print-Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Report

Refractory discoid lupus erythematosus responds to rituximab.

Subjects: Lupus Erythematosus, Discoid/Lupus Erythematosus, Discoid/Lupus Erythematosus, Discoid/*complications ; Rituximab/Rituximab/Rituximab/*pharmacology; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/metabolism

  • Source: The Australasian journal of dermatology [Australas J Dermatol] 2021 May; Vol. 62 (2), pp. e341-e343. Date of Electronic Publication: 2020 Nov 20.Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 0135232 Publication Model: Print-Electronic Cited

Record details

Read Online Read More Add to Saved list
×
  • 1-10 of  35,990 results for ""RITUXIMAB""